复星医药(02196.HK):目前未有证据表明该批暂停接种之复必泰疫苗存安全风险
复星医药(02196.HK)公布,对於批号为210102的(BioNTech)复必泰疫苗药瓶封盖有关的包装瑕疵,且港澳即日起暂停该批复必泰疫苗接种,直至调查结束的事宜,公司指目前未有证据表明相关批次产品安全可能存在风险,具体情况以最终调查结果为准。该疫苗是次暂停使用并作封存,对於相关批次疫苗在香港、澳门的後续接种安排可能存在影响,具体以调查结果为准。
公司又指,该疫苗是次暂停使用并作封存,预计不会对集团的正常生产经营造成重大影响。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.